Remove 2023 Remove Healthcare Remove Pharmaceutical manufacturing
article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

This poses a significant challenge for pharmaceutical manufacturers, not least because of the technical challenges related to operations, supply chain and the environment. This article explores the potential impact of the proposal and considers how manufacturers can ensure the safety and reliability of their products.

article thumbnail

APL Health Care (Aurobindo )-Walk-In Interviews for IPQA/ Microbiology On 4th Feb’ 2023

Pharma Pathway

APL Health Care (Aurobindo )-Walk-In Interviews for IPQA/ Microbiology On 4th Feb’ 2023 Job Description Company Profile: Aurobindo Pharma Ltd’ (APL). APL is a growing India multinational pharmaceutical manufacturing firm with turnover of over US$2.8

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Year in review: EPR’s top stories of 2023

European Pharmaceutical Review

At the beginning of this year, EPR reported on the potential blockbuster pharmaceutical drugs to watch in 2023. The year 2023 also brought much advancement in the Alzheimer’s space for the pharmaceutical industry. Since then, EPR has covered developments for several of the therapies highlighted in the report.

article thumbnail

Pharma unite to secure renewable energy in key manufacturing markets

European Pharmaceutical Review

For the first time, companies across the global healthcare sector, including AstraZeneca , GSK, Novo Nordisk and Roche, have united to discuss with energy providers in China and India, about scaling renewable power across their supply chains. This step is important as these countries are key markets for pharmaceuticals manufacturing.

article thumbnail

Sandoz and Teva achieve first-of-a-kind manufacturing certification

European Pharmaceutical Review

Impact of the AMR certification Following the launch of the certification programme’s in June 2023, a range of antibiotic products have successfully completed the certification process within each of the organisations, BSI confirmed.

article thumbnail

ISPOR 2023: A Focus on Quality

Prognos Health

Todd Somsel , Commercial Lead, RWD Marketplace The acceptance and application of real-world evidence (RWE) by stakeholders across the healthcare industry continues its rapid pace of growth.

article thumbnail

ISPOR 2023: A Focus on Quality

Prognos Health

Todd Somsel , Commercial Lead, RWD Marketplace The acceptance and application of real-world evidence (RWE) by stakeholders across the healthcare industry continues its rapid pace of growth.